Tananbaum James B.'s Form 4 filing
Pardes Biosciences, Inc. (PRDS) · filed Dec 23, 2021
- Accession no.
- 0001213900-21-067341
- Filed
- Dec 23, 2021, 4:52 PM ET
- Trade date
- Dec 22, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $3.25M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tananbaum James B.CIK 0001581754 | Director, 10% Owner |
| Foresite Capital Fund V, L.P.CIK 0001792204 | 10% Owner |
| Foresite Capital Opportunity Fund V, L.P.CIK 0001792205 | 10% Owner |
| Foresite Capital Management V, LLCCIK 0001792206 | 10% Owner |
| Foresite Capital Opportunity Management V, LLCCIK 0001792207 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 22, 2021 | Common Stock | PPurchaseAcquired | +325,000 | $10.00 | +$3,250,000 | 325,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.